Outcome of COVID-19 in allogeneic stem cell transplant recipients: results from the EPICOVIDEHA registry

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F23%3A00013522" target="_blank" >RIV/00023736:_____/23:00013522 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/23:00130698 RIV/65269705:_____/23:00079416 RIV/00179906:_____/23:10464718
Result on the web
<a href="https://doi.org/10.3389/fimmu.2023.1125030" target="_blank" >https://doi.org/10.3389/fimmu.2023.1125030</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fimmu.2023.1125030" target="_blank" >10.3389/fimmu.2023.1125030</a>

Result language
angličtina
Original language name
Outcome of COVID-19 in allogeneic stem cell transplant recipients: results from the EPICOVIDEHA registry
Original language description
The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. Mortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)